

THE NEURO-SYSMED ANNUAL SYMPOSIUM 2025

18-19 NOVEMBER 2025,

SOLSTRAND HOTEL, BERGEN/OS, NORWAY

PREFINAL PROGRAM

DAY 1 — TUESDAY NOVEMBER 18

09:00-10:20 Registration & coffee
10:20-10:30 Welcome – Center Director **Charalampos Tzoulis** and Co-Director **Kjell-Morten Myhr**

SESSION 1: PREVENTION IN MS. Chair: **Øivind Torkildsen**

10:30-11:00 **Christian Munz** (BEHIND-MS consortium): EBV infected B cells as trailblazers for inflammatory lymphocytes into the CNS
11:00-11:30 **Gavin Giovannoni**: EBV theory to practice - pragmatic ways to prevent MS
11:30-12:00 **Fredrik Piehl**: Optimizing B-cell depletion: dosing, intervals and preventive potential
12:00-13:00 *Lunch*

SESSION 2: PREVENTION IN NEURODEGENERATION. Chair: **Charalampos Tzoulis**

13:00-13:30 **Alberto Ascherio**: Viral infections and risk of Alzheimer disease
13:30-14:00 **Arcadi Navarro Cuartiellas**: Ageing and Alzheimer's; the need for a revolution in Brain Health
14:00-14:30 **Johannes J. Gaare**: NOR-RBD; a Norwegian longitudinal cohort of prodromal α -synucleinopathy
14:30-15:00 *Coffee Break*

SESSION 3: BREAKING NEWS. Chair: **Xavier Montalban**

15:00-15:25 **Øivind Torkildsen**: OVERLORD
15:25-15:40 **Haakon Berven**: N-DOSE
15:40-15:55 **Christopher Elnan Kvistad**: SMART-MS
15:55-16:10 **Christian Dölle**: NADbrain
19:00-20:00 POSTER SESSION
20:00 *Dinner*

DAY 2 — WEDNESDAY NOVEMBER 19

SESSION 4: PLATFORM TRIALS & OTHER DESIGNS. Chair: **Kjell-Morten Myhr**

09:00-09:30 **Suvankar Pal**: MND SMART: Motor Neuron Disease Systematic Multi Arm Adaptive Randomised trial – Delivering innovative, efficient, and definitive trials for people with MND
09:30-10:00 **Thomas Foltynie & Camille Carroll**: A Multi-Arm, Multi-Stage Platform trial for Parkinson's disease- EJS ACT-PD
10:00-10:30 **Pareesh Malhotra**: AD-SMART: Preparing a platform trial in clinical Alzheimer's Disease
10:30-10:50 *Coffee break*
10:50-11:20 **Jeremy Chataway**: The OCTOPUS trial: a MAMS trial in Progressive Multiple Sclerosis – design and implementation
11:20-11:50 **Xavier Montalban**: The "ideal trial design" in the era of high-efficacy therapy for MS
12:00-13:00 *Lunch*
13:00-13:30 **Charalampos Tzoulis**: Norwegian platform initiatives in PD: SLEIPNIR & HYDRA
13:30-14:00 **Marcus Werner Koch**: Phase 2 futility trials in neurological diseases
14:00-14:15 Closing remarks & poster prizes

